A Phase 1 interventional study of Evolocumab and Placebo in Hyperlipidemia, sponsored by Amgen. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-02.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 17th largest by enrollment, is the only one that started in 2010, is one of 2 in phase 1, and was the 1st registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 16th largest by enrollment, is the only one that started in 2010, is one of 2 in phase 1, and was the 1st registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.
Participants receiving low-to-moderate-dose statins were randomized in a 1:3 ratio to receive subcutaneous placebo or evolocumab and enrolled sequentially into one of 5 dose-escalation cohorts:
Participants receiving high-dose statins were randomized 1:3 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 6).
Participants diagnosed with familial hypercholesterolemia (HeFH) were randomized 1:2 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 7).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diabetes mellitus with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
Biological: Evolocumab
Participants received matching placebo dose regimens by subcutaneous injection.
Biological: Placebo
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Number of Participants With Adverse Events
The relationship of each adverse event to the investigational product was assessed by the investigator. A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening (places the subject at immediate risk of death) * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard.
Time frame: From the first dose of study drug until Day 85
Number of Participants With Anti-Evolocumab Antibodies
Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-evolocumab binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-evolocumab neutralizing antibodies
Time frame: From the first dose of study drug until Day 85
Maximum Observed Plasma Concentration (Cmax) of Evolocumab
Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 800 ng/mL.
Time frame: Day 1, predose and Days 4, 8, 15, 22, 29, 36, 40, 43, 50, 57, 64, 71, 78, and 85
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab
Area under the unbound evolocumab serum concentration-time curve from time of last dose to time of last quantifiable concentration following the last dose of evolocumab.
Time frame: Day 29 predose (last dose for Cohorts 3-7) and Days 36 (predose for Cohorts 1 and 2), 40, 43, 50, 57, 64, 71, 78, and 85
Percent Change From Baseline to End of the Dosing Interval in LDL-C
Time frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
Percent Change From Baseline to End of the Dosing Interval in PCSK9
Serum PCSK9 concentrations were determined by using a qualified enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 15 ng/mL.
Time frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
This study enrolled hypercholesterolemic adults receiving stable statin therapy (7 cohorts: 5 on low-to-moderate-dose statins, 1 on high-dose statin therapy, and 1 with heterozygous familial hypercholesterolemia (HeFH) (score ≥9, World Health Organization criteria). First patient enrolled 28 June 2010. Last patient enrolled 24 June 2011.
| Milestone | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 7 | 6 | 7 | 7 | 6 | 2 | 9 | 2 | 4 |
| Received treatment | 10 | 6 | 6 | 6 | 6 | 6 | 2 | 9 | 2 | 4 |
| Completed | 10 | 6 | 6 | 6 | 6 | 6 | 2 | 9 | 2 | 4 |
| Not completed | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The relationship of each adverse event to the investigational product was assessed by the investigator. A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening (places the subject at immediate risk of death) * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard.
| participants | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 7 | 2 | 5 | 4 | 6 | 3 | 1 | 7 | 1 | 1 |
| Treatment-related adverse events | 1 | 1 | 0 | 1 | 6 | 0 | 1 | 2 | 0 | 0 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinuations due to adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths on study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 800 ng/mL.
| μg/mL | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Evolocumab | — | — | 20.3 ± 13.2 | 62.8 ± 22.7 | 63.6 ± 11.2 | 16.3 ± 10.8 | 14.7 ± 2.9 |
Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-evolocumab binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-evolocumab neutralizing antibodies
| participants | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Binding Antibodies | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutralizing Antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the unbound evolocumab serum concentration-time curve from time of last dose to time of last quantifiable concentration following the last dose of evolocumab.
| day*μg/mL | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab | — | — | 226 ± 249 | 1200 ± 634 | 903 ± 280 | 181 ± 157 | 165 ± 69 |
| percent change | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline to End of the Dosing Interval in LDL-C | 3.14 ± 33.73 | -23.79 ± 21.57 | -51.76 ± 18.29 | -69.58 ± 18.13 | -74.65 ± 3.47 | -62.01 ± 11.43 | -3.01 ± 3.09 | -61.82 ± 17.67 | -4.89 ± 0.82 | -62.91 ± 16.04 |
Serum PCSK9 concentrations were determined by using a qualified enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 15 ng/mL.
| percent change | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline to End of the Dosing Interval in PCSK9 | 6.00 ± 25.49 | -42.07 ± 16.99 | -64.46 ± 3.70 | -70.42 ± 16.05 | -91.49 ± 6.45 | -32.72 ± 29.41 | 43.60 ± 51.39 | -62.50 ± 18.33 | 36.76 ± 12.54 | -68.52 ± 10.67 |
Collected over From the first dose of study drug until Day 85. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/10 (0%) | 7/10 (70%) |
| Evolocumab 14 mg QW × 6 | — | 0/6 (0%) | 2/6 (33.3%) |
| Evolocumab 35 mg QW × 6 | — | 0/6 (0%) | 5/6 (83.3%) |
| Evolocumab 140 mg Q2W × 3 | — | 0/6 (0%) | 4/6 (66.7%) |
| Evolocumab 280 mg Q2W × 3 | — | 0/6 (0%) | 6/6 (100%) |
| Evolocumab 420 mg Q4W × 2 | — | 0/6 (0%) | 3/6 (50%) |
| High Dose Statin - Placebo | — | 0/2 (0%) | 1/2 (50%) |
| High Dose Statin - Evolocumab 140 mg Q2W × 3 | — | 0/9 (0%) | 7/9 (77.8%) |
| HeFH - Placebo | — | 0/2 (0%) | 1/2 (50%) |
| HeFH - Evolocumab 140 mg Q2W × 3 | — | 0/4 (0%) | 1/4 (25%) |
| Event | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain lowerGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/9 | 0/2 | 0/4 |
| Injection site painGeneral disorders | 0/10 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/2 | 0/9 | 0/2 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/10 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/9 | 0/2 | 0/4 |
| Neck massMusculoskeletal and connective tissue disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/9 | 0/2 | 0/4 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 0/9 | 1/2 | 0/4 |
| Varicose veinVascular disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/9 | 0/2 | 0/4 |
| ConstipationGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/2 | 0/9 | 0/2 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 0/10 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/2 | 0/9 | 0/2 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/2 | 0/9 | 0/2 | 1/4 |
| Injection site haematomaGeneral disorders | 2/10 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/2 | 1/9 | 0/2 | 0/4 |
Safety analysis set (all participants who received at least 1 dose of study drug).
| Age, Continuous(years) | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55.8 ± 7.5 | 61.3 ± 4.0 | 63.7 ± 6.3 | 56.2 ± 7.3 | 56.3 ± 8.6 | 53.8 ± 4.9 | 62.0 ± 1.4 | 58.2 ± 7.6 | 54.5 ± 10.6 | 45.0 ± 15.1 | 56.9 ± 8.4 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 1 | 3 | 4 | 3 | 1 | 3 | 1 | 0 | 26 |
| Male | 4 | 2 | 5 | 3 | 2 | 3 | 1 | 6 | 1 | 4 | 31 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White or Caucasian | 9 | 6 | 6 | 4 | 6 | 3 | 2 | 7 | 2 | 2 | 47 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 0 | 7 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Japanese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aborigine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Low-Density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 108.9 ± 21.9 | 126.7 ± 22.1 | 106.5 ± 29.4 | 113.7 ± 14.5 | 105.8 ± 17.0 | 120.3 ± 33.0 | 99.0 ± 31.1 | 100.2 ± 25.5 | 168.5 ± 57.3 | 134.5 ± 31.1 | 114.1 ± 27.8 |
| Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration(ng/mL) | Placebo | Evolocumab 14 mg QW × 6 | Evolocumab 35 mg QW × 6 | Evolocumab 140 mg Q2W × 3 | Evolocumab 280 mg Q2W × 3 | Evolocumab 420 mg Q4W × 2 | High Dose Statin - Placebo | High Dose Statin - Evolocumab 140 mg Q2W × 3 | HeFH - Placebo | HeFH - Evolocumab 140 mg Q2W × 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 429.0 ± 93.1 | 491.2 ± 157.9 | 399.8 ± 116.7 | 384.8 ± 88.0 | 373.7 ± 96.0 | 459.0 ± 163.4 | 382.5 ± 82.7 | 486.6 ± 214.0 | 478.5 ± 94.0 | 396.0 ± 86.4 | 432.0 ± 133.6 |
No study locations are listed for this record.
Ran from Jun 2010 to primary completion in Sep 2011, 15 months.
Results were first posted in Oct 2015, 4 years 1 month after primary completion.
Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 15 months is above that.
Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab